Rebecca Epperly, MD, on Emerging Clinical Research With Cell Therapy in Leukemia, Lymphoma

“The big areas we see people addressing in the CAR space is how to prevent relapse, or treat patients who relapse after they've gotten the first round of CD19 CAR T cells? And then how do we get to other groups? … Those are really kind of key areas of interests moving forward that we've been seeing a lot in the preclinical space. And this is kind of one of the first rounds of seeing this very early clinical data come out.”

The cellular immunotherapies session at 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, highlighted early clinical data on emerging therapies including Unicar-T-CD123 for relapsed/refractory (R/R) acute myeloid leukemia (AML), UCART123v1.2 in the same indication, and CD30.CAR-T cells in classical Hodgkin lymphoma (CHL).

CGTLive spoke with the session’s moderator Rebecca Epperly, MD, instructor and clinician scientist, bone marrow transplant and cellular therapy, St. Jude Children’s Research Hospital, about her insights into the presentations and current trends in early clinical research in acute leukemias and HL. She touched on some of these trends, including addressing treatment after relapse with chimeric antigen receptor (CAR) T-cell therapy and underrepresented areas of disease with cell therapy.

Click here to read more coverage of the ASH 2022 meeting.

REFERENCE

Epperly R. Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans. Session 704.